menu
    • menu
    [{"orgOrder":0,"company":"TRIO Pharmaceuticals","sponsor":"FBVF","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"CD33 TRAILBody","moa":"CD33","graph1":"Oncology","graph2":"Preclinical","graph3":"TRIO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRIO Pharmaceuticals \/ FBVF","highestDevelopmentStatusID":"4","companyTruncated":"TRIO Pharmaceuticals \/ FBVF"},{"orgOrder":0,"company":"TRIO Pharmaceuticals","sponsor":"Ajinomoto Bio-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"TRIO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TRIO Pharmaceuticals \/ TRIO Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"TRIO Pharmaceuticals \/ TRIO Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by TRIO Pharmaceuticals

    Menu

    TRIO Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TRIO Pharmaceuticals

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            TRIO Pharmaceuticals

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD33 TRAILBody

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : FBVF

                            Deal Size : $3.1 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            TRIO Pharmaceuticals Raises $3.1M to Advance Cancer Therapeutics Pipeline

                            Details : TRIO will use the net proceeds to advance cancer therapeutics pipeline, including CD33 TRAILBody in preclinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : CD33 TRAILBody

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : FBVF

                            Deal Size : $3.1 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TRIO Pharmaceuticals

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            TRIO Pharmaceuticals

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Ajinomoto Bio-Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Nove...

                            Details : Trio Pharmaceuticals and Ajinomoto Bio-Pharma Services will evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 30, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Ajinomoto Bio-Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth